This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Ayvakyt | Medison Pharma Canada Inc. | For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. | 2026-10-07 |
| Ringza | Duchesnay Inc. | For use by women of reproductive potential to prevent pregnancy | 2026-10-13 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Gonal-F | EMD Serono Canada, a division of EMD Inc. | Luveris, for the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin | 2026-07-07 | 2026-10-13 |
| Elahere | AbbVie Corporation | For the treatment of adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens | 2026-09-23 | 2026-10-20 |
| Luveris | EMD Serono Canada, a division of EMD Inc. | For the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin | 2026-07-07 | 2026-10-13 |
| Cabometyx | Ipsen Biopharmaceuticals Canada, Inc. | For the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET). | 2026-05-29 | 2026-10-19 |
| Loqtorzi | Apotex Inc. | In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). | 2026-07-02 | 2026-10-13 |
| Lyvdelzi | Gilead Sciences Canada Inc. | For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. | 2026-02-11 | 2026-10-16 |
| Solufy | Psychotic disorders, mood disorders, and major depressive disorder | 2026-06-03 | 2026-10-16 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | LOE date | Close date |
|---|---|---|---|---|
| Talvey (Active ENP) | Janssen Inc. | For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy. | 2026-07-28 | 2026-10-23 |
| Jatenzo | Tolmar Pharmaceuticals Canada, Inc. | Testosterone replacement therapy | 2026-07-27 | 2026-10-22 |
| Isturisa | Recordati Rare Diseases Canada Inc. | For the treatment of adult patients with Cushing's disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option. | 2026-04-28 | 2026-10-22 |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
There have been no negotiations which pCPA decided not to pursue in the last four weeks